ANGLE plc (AGL.L, ANPCY) said that it has reached an agreement with AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response or 'DDR' assay for the detection of micronuclei in circulating tumour cells as a measure of DDR.As per the deal, ANGLE will develop a methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response.

ANGLE plc（AGL.L，ANPCY）表示，它已经与阿斯利康公司达成协议，开发和验证一种利用ANGLE现有的DNA损伤反应或“DDR”检测方法检测循环肿瘤细胞中的微核作为DDR的测量方法。根据协议，ANGLE将基于其现有的基于pKAP1 CTC的DDR测定法开发一种CTC微核检测方法，该方法可测量DNA损伤反应中关键蛋白的表达。

Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two DDR assays in 2023. The 6-month development phase is worth an initial 150,000 pounds to ANGLE.For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News.

分析开发将在英国吉尔福德的ANGLE实验室进行，随后该公司于2023年开发并推出了两种DDR分析。6个月的开发阶段最初价值150000英镑。有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。